BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» Sab's fully human anti-thymocyte immunoglobulin cleared to enter clinic in Australia for type 1 diabetes
To read the full story,
subscribe
or
sign in
.
Endocrine/Metabolic
Sab's fully human anti-thymocyte immunoglobulin cleared to enter clinic in Australia for type 1 diabetes
Oct. 20, 2023
No Comments
Sab Biotherapeutics Inc. has obtained human research ethics committee (HREC) approval in Australia to commence a first-in-human phase I trial investigating SAB-142 for type 1 diabetes.
BioWorld Science
Diabetes
Endocrine/metabolic
Australia
